Boston Sci Q2 Revenue Up 23 Percent

Boston Scientific (NYSE:BSX), a leader in medical devices for cardiovascular and surgical markets, reported its second-quarter 2025 results on July 23, 2025. The company posted revenue and earnings well above Wall Street expectations for the period, with revenue of $5.06 billion topping analyst estimates of $4.89 billion. Adjusted (non-GAAP) earnings per share (EPS) landed at $0.75, also ahead of the projected $0.73. Both numbers exceeded the upper end of Boston Scientific's own guidance. Management characterized the quarter as one marked by strong sales growth, led by outperformance in its Cardiovascular segment, while acknowledging margin pressures ahead from newly enacted tariffs and special attention needed for international and MedSurg business trends. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Boston Scientific develops and markets a wide range of medical technologies, supplying hospitals and physicians around the world. Its two main business segments are Cardiovascular, which covers devices for heart and blood vessel conditions, and MedSurg, which provides a lineup of minimally invasive tools for surgery, urology, endoscopy, and pain management. The company's top-selling families include the WATCHMAN FLX left atrial appendage closure device (helps prevent strokes in certain heart patients), and WaveWriter Alpha spinal cord stimulators (pain management devices).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool